SMARCB1 and neoplasm: Similarly, to the orthotopic SMARCB1 KO xenografts, the SMARCB1-deficient PDX model demonstrated a significant inhibition of tumor growth with TTI-101 compared to vehicle treatment (Fig. 6A, B).